These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15747431)

  • 41. Tapping into combination pills for HIV.
    Hughes B
    Nat Rev Drug Discov; 2009 Jun; 8(6):439-40. PubMed ID: 19483700
    [No Abstract]   [Full Text] [Related]  

  • 42. FDA makes final approvals.
    AIDS Patient Care STDS; 2006 May; 20(5):381. PubMed ID: 16758553
    [No Abstract]   [Full Text] [Related]  

  • 43. Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
    Ingiliz P; Krznaric I; Obermeier M
    AIDS; 2013 Feb; 27(4):667-8. PubMed ID: 23364445
    [No Abstract]   [Full Text] [Related]  

  • 44. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
    Rosso R; Di Biagio A; Maggiolo F; Nulvesu L; Callegaro AP; Taramasso L; Bruzzone B; Viscoli C
    AIDS Care; 2012; 24(1):54-8. PubMed ID: 21800951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early virological failure with a combination of tenofovir, didanosine and efavirenz.
    Podzamczer D; Ferrer E; Gatell JM; Niubo J; Dalmau D; Leon A; Knobel H; Polo C; Iniguez D; Ruiz I
    Antivir Ther; 2005; 10(1):171-7. PubMed ID: 15751775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Labeling changes for tenofovir.
    AIDS Patient Care STDS; 2004 Jan; 18(1):55. PubMed ID: 15006195
    [No Abstract]   [Full Text] [Related]  

  • 47. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
    Pujari S; Dravid A; Gupte N; Joshi K; Bele V
    Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention. Using PrEP cost-effective in high-risk MSM groups.
    AIDS Policy Law; 2012 Jun; 27(7):1. PubMed ID: 22803211
    [No Abstract]   [Full Text] [Related]  

  • 49. Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
    Estebanez M; Stella-Ascariz N; Ruiz-Carrascoso G; Zamora FX; García-Bujalance S; Bernardino JI; Pérez-Valero I; Martin-Quirós A; Mingorance J; Arribas JR
    AIDS; 2013 Jan; 27(1):141-4. PubMed ID: 22914581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
    Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
    Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 52. Atripla approval in Europe.
    AIDS Patient Care STDS; 2006 Dec; 20(12):887. PubMed ID: 17192153
    [No Abstract]   [Full Text] [Related]  

  • 53. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 55. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
    Cooper V; Moyle GJ; Fisher M; Reilly G; Ewan J; Liu HC; Horne R;
    AIDS Care; 2011 Jun; 23(6):705-13. PubMed ID: 21476152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
    Expert Rev Clin Immunol; 2010 Mar; 6(2):186. PubMed ID: 20402380
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV transmission may be prevented by intravaginal tenofovir ring.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2239. PubMed ID: 23359902
    [No Abstract]   [Full Text] [Related]  

  • 58. Medicines Control Council and registration backlog of antiretrovirals.
    Gosling J
    S Afr Med J; 2007 Apr; 97(4):232. PubMed ID: 17446940
    [No Abstract]   [Full Text] [Related]  

  • 59. Infectious disease: New HIV-1 prodrug shows promise in phase III trials.
    Stone L
    Nat Rev Urol; 2015 Jun; 12(6):301. PubMed ID: 25941789
    [No Abstract]   [Full Text] [Related]  

  • 60. [Sustiva approved in Germany. The first HIV drug with single daily dosage].
    Förster E
    Pharm Unserer Zeit; 1999 Sep; 28(5):271-2. PubMed ID: 10546498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.